Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
The company has been consistently reducing debt
Total income grew in the quarter
The govt has rolled out three schemes for promoting the manufacture of API
Drug formulations and biologics make impressive gains
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
